X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1406) 1406
Publication (206) 206
Book Review (39) 39
Newsletter (25) 25
Book Chapter (10) 10
Book / eBook (7) 7
Dissertation (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1168) 1168
index medicus (924) 924
pharmacology & pharmacy (872) 872
cytochrome p-450 (600) 600
male (524) 524
cytochrome p-450 enzyme system - metabolism (476) 476
pharmacokinetics (455) 455
drug interactions (427) 427
metabolism (404) 404
female (401) 401
animals (375) 375
adult (330) 330
cytochrome p450 (320) 320
physiological aspects (297) 297
middle aged (266) 266
cytochrome p-450 enzyme system - genetics (228) 228
pharmacogenetics (226) 226
enzymes (216) 216
in-vitro (215) 215
analysis (204) 204
genotype (199) 199
metabolites (198) 198
research (192) 192
aryl hydrocarbon hydroxylases - genetics (187) 187
toxicology (182) 182
pharmacology/toxicology (180) 180
human liver-microsomes (177) 177
genetic aspects (161) 161
cytochrome p-450 cyp3a - metabolism (160) 160
aged (153) 153
pharmacology (152) 152
area under curve (151) 151
polymorphism, genetic (147) 147
p-glycoprotein (143) 143
genetic polymorphisms (133) 133
microsomes, liver - metabolism (133) 133
young adult (133) 133
biochemistry & molecular biology (132) 132
inhibition (132) 132
aryl hydrocarbon hydroxylases - metabolism (131) 131
liver (129) 129
cytochrome p-450 cyp2c8 (127) 127
drug metabolism (126) 126
cytochrome (118) 118
cytochrome p-450 cyp2c9 (116) 116
drug-drug interactions (113) 113
polymorphism (113) 113
cytochrome p-450 enzyme inhibitors (109) 109
cancer (107) 107
cyp2c9 (106) 106
cyp3a4 (106) 106
microsomes, liver - enzymology (106) 106
biotransformation (103) 103
biomedicine (102) 102
expression (101) 101
dose-response relationship, drug (100) 100
drugs (100) 100
medicine & public health (100) 100
health aspects (99) 99
administration, oral (98) 98
rats (98) 98
article (96) 96
cross-over studies (96) 96
care and treatment (91) 91
cyp2c8 (91) 91
internal medicine (86) 86
enzyme inhibitors - pharmacology (85) 85
microsomes, liver - drug effects (85) 85
plasma-concentrations (85) 85
hydroxylation (84) 84
pharmaceutical preparations - metabolism (83) 83
drug therapy (80) 80
kinetics (79) 79
liver - enzymology (79) 79
arachidonic acid (78) 78
liver - metabolism (78) 78
models, biological (78) 78
oncology (78) 78
alleles (77) 77
pharmacodynamics (77) 77
cytochrome p-450 cyp3a (75) 75
mice (75) 75
half-life (73) 73
polymorphism, single nucleotide (73) 73
adolescent (72) 72
cytochrome p-450 cyp2c19 (69) 69
induction (69) 69
polymorphisms (69) 69
cyp2c19 (68) 68
mass spectrometry (68) 68
pharmacotherapy (68) 68
arachidonic-acid (65) 65
healthy-volunteers (65) 65
cytochrome-p450 (64) 64
epoxyeicosatrienoic acids (64) 64
hypoglycemic agents - pharmacokinetics (64) 64
pharmacy (64) 64
soluble epoxide hydrolase (64) 64
risk factors (63) 63
drug-drug interaction (62) 62
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 02/2016, Volume 81, Issue 2, pp. 313 - 315
Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2015, Volume 55, Issue 9, pp. 1012 - 1023
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 2016, Volume 44, Issue 8, pp. 1364 - 1371
The glucose-lowering drug pioglitazone undergoes hepatic CYP2C8-mediated biotransformation to its main metabolites. The antiplatelet drug clopidogrel is... 
IN-VITRO | PHARMACOKINETICS | DEPENDENT INHIBITOR | SIMVASTATIN ACID | SLCO1B1 POLYMORPHISM | PHARMACOLOGY & PHARMACY | CERIVASTATIN | TRANSPORTING POLYPEPTIDE 1B1 | TYPE-2 DIABETES-MELLITUS | CYTOCHROME-P450 3A4 | DRUG-DRUG INTERACTIONS | Cytochrome P-450 CYP2C8 Inhibitors - administration & dosage | Area Under Curve | Humans | Half-Life | Male | Metabolic Clearance Rate | Healthy Volunteers | Thiazolidinediones - administration & dosage | Thiazolidinediones - pharmacokinetics | Platelet Aggregation Inhibitors - blood | Young Adult | Hypoglycemic Agents - blood | Drug Interactions | Hypoglycemic Agents - administration & dosage | Biotransformation | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Pharmacogenomic Variants | Ticlopidine - administration & dosage | Adult | Female | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Cytochrome P-450 CYP2C8 - metabolism | Platelet Aggregation Inhibitors - adverse effects | Hypoglycemic Agents - pharmacokinetics | Drug Administration Schedule | Risk Assessment | Administration, Oral | Genotype | Cytochrome P-450 CYP2C8 Inhibitors - adverse effects | Thiazolidinediones - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Phenotype | Finland | Cytochrome P-450 CYP2C8 - genetics | Hypoglycemic Agents - adverse effects | Thiazolidinediones - blood | Ticlopidine - blood
Journal Article
Journal Article
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2017, Volume 83, Issue 12, pp. 2778 - 2788
Aims Based on in vitro data, there is evidence to suggest that cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite,... 
pharmacokinetics | rifampicin | selexipag | CYP2C8 | drug interactions | gemfibrozil | PULMONARY ARTERIAL-HYPERTENSION | TREPROSTINIL | REPAGLINIDE | CLOPIDOGREL | CONCISE GUIDE | PHARMACOLOGY | TOLERABILITY | PROSTACYCLIN RECEPTOR AGONIST | PHARMACOLOGY & PHARMACY | INHIBITOR | Prodrugs - administration & dosage | Activation, Metabolic | Cytochrome P-450 CYP2C8 Inhibitors - administration & dosage | Acetates - adverse effects | Acetates - blood | Area Under Curve | Humans | Middle Aged | Pyrazines - administration & dosage | Antihypertensive Agents - administration & dosage | Half-Life | Male | Metabolic Clearance Rate | Gemfibrozil - adverse effects | Healthy Volunteers | Acetamides - blood | Young Adult | Rifampin - adverse effects | Drug Interactions | Acetamides - adverse effects | Cytochrome P-450 CYP2C8 Inducers - adverse effects | Adult | Cytochrome P-450 CYP2C8 - metabolism | Rifampin - administration & dosage | Gemfibrozil - administration & dosage | Cytochrome P-450 CYP2C8 Inducers - administration & dosage | Acetamides - pharmacokinetics | Risk Assessment | Cytochrome P-450 CYP2C8 Inhibitors - adverse effects | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Cross-Over Studies | Prodrugs - adverse effects | Acetates - administration & dosage | Prodrugs - pharmacokinetics | Pyrazines - pharmacokinetics | Adolescent | Pyrazines - adverse effects | Pyrazines - blood | Germany | Acetamides - administration & dosage | Acetates - pharmacokinetics | Metabolites | Gemfibrozil | Cytochrome P-450 | Nausea | Drug therapy, Combination | Rifampin | Fibric acids
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 09/2018, Volume 104, Issue 3, pp. 495 - 504
The oxidation of montelukast is mainly mediated by cytochrome P450 (CYP) 2C8, but other mechanisms may contribute to its disposition. In healthy volunteers, we... 
GEMFIBROZIL | PHARMACOKINETICS | PLASMA-CONCENTRATIONS | MARKEDLY INCREASES | PHARMACOLOGY & PHARMACY | ACUTE CORONARY SYNDROMES | LEUKOTRIENE-RECEPTOR ANTAGONIST | CYP2C8 SUBSTRATE PIOGLITAZONE | DRUG-DRUG INTERACTIONS | Cytochrome P-450 CYP2C8 Inhibitors - administration & dosage | Inactivation, Metabolic | Quinolines - blood | Acetates - adverse effects | Acetates - blood | Humans | Leukotriene Antagonists - pharmacokinetics | Substrate Specificity | Male | Clopidogrel - administration & dosage | Healthy Volunteers | Quinolines - administration & dosage | Quinolines - pharmacokinetics | Young Adult | Drug Interactions | Leukotriene Antagonists - administration & dosage | Computer Simulation | Platelet Aggregation Inhibitors - administration & dosage | Pharmacogenomic Variants | Adult | Female | Cytochrome P-450 CYP2C8 - metabolism | Prasugrel Hydrochloride - administration & dosage | Leukotriene Antagonists - adverse effects | Platelet Aggregation Inhibitors - adverse effects | Pharmacogenetics | Oxidation-Reduction | Risk Assessment | Cytochrome P-450 CYP2C8 Inhibitors - adverse effects | Prasugrel Hydrochloride - adverse effects | Cross-Over Studies | Acetates - administration & dosage | Models, Biological | Leukotriene Antagonists - blood | Clopidogrel - adverse effects | Cytochrome P-450 CYP2C8 - genetics | Quinolines - adverse effects | Acetates - pharmacokinetics | Research | Basic Medicine | Farmakologi och toxikologi | Medical and Health Sciences | Pharmacology and Toxicology | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 8/2017, Volume 56, Issue 8, pp. 977 - 985
The aims of this study were to determine the effects of the CYP2C8*3 and *4 polymorphisms on imatinib metabolism and plasma imatinib concentrations in chronic... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | TYROSINE KINASE INHIBITORS | IN-VITRO | ABCB1 | GENETIC POLYMORPHISMS | TRANSPORTER POLYMORPHISMS | POPULATION PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | CLINICAL PHARMACOKINETICS | N-DEMETHYLATION | CYP3A4 | P-GLYCOPROTEIN | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imatinib Mesylate - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Imatinib Mesylate - pharmacokinetics | Imatinib Mesylate - administration & dosage | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Cytochrome P-450 CYP2C8 - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Pharmacogenetics - methods | Cytochrome P-450 CYP2C8 - drug effects | Genotype | Protein Kinase Inhibitors - blood | Polymorphism, Genetic | Protein Kinase Inhibitors - administration & dosage | Imatinib Mesylate - blood | Receptor Protein-Tyrosine Kinases - genetics | Aged | Cytochrome P-450 CYP2C8 - genetics | Clinical Trials, Phase II as Topic | Protein Kinase Inhibitors - metabolism | Care and treatment | Cancer patients | Chronic myeloid leukemia | Research | Cytochrome | Studies | Plasma | Genotype & phenotype | Enzymes | Ratios | Metabolites | Leukemia | Metabolism | Patients | Drug dosages
Journal Article